In 2020, oncology drugs will still be the most lively track for new drug research and development in the world. Gilead acquired Immunomedics for US$21 billion and acquired Trodelvy, an antibody-conjugated drug targeting Trop-2, which completely detonated the enthusiasm for ADC drug R&D investment. Amgen has completed Sotorasib's key clinical research, submitted a marketing application, and obtained FDA priority review qualifications, and is about to break the new drug development deadlock of the difficult drug target KRAS...
Oncology drugs are also the drug market that attracts the most money and attracts the most attention. Many pharmaceutical giants have gained a lot in this field. Now, who are the top 10 pharmaceutical giants in the global oncology business? Now, let's find the top 10 oncology pharmaceutical companies in 2020.
|Top 10 Oncology Pharmaceutical Companies 2020 ($ billion)|
|Rank||Company||Pharmaceutical Business Revenue||Oncology Business Revenue||Growth||Proportion|
|5||Johnson & Johnson||45.572||12.367||15.70%||27.10%|
|Note: Roche's revenue unit is Swiss francs|
Eli Lilly ranks among the TOP 10 oncology drug companies, mainly relying on Alimta (Pemetrexed), which has been on the market for 17 years, and still had a 10% growth in 2020. In addition to Alimta, Eli Lilly's oncology drugs include Cyramza (Ramucirumab), and breast cancer drug Verzenio (Abemaciclib).
Verzenio, the third CDK4/6 inhibitor on the market, has increased its sales revenue by 57% in 2020 to reach US$913 million and is expected to become a new pillar of Eli Lilly's oncology products.
In 2020, Eli Lilly's oncology business revenue was US$5.158 billion, accounting for 21% of the company's total revenue. With increasing efforts in the field of oncology and the launch of new products, Eli Lilly’s oncology business is still expanding.
AbbVie's most prominent label is Humira. Even after the acquisition of Allergan, Humira still accounts for 43% of its total revenue. In the oncology field, although AbbVie's overall business revenue volume is not as shocking as Humira, the specific products are still very dazzling.
Imbruvica and Venclexta are two core products of AbbVie in the field of oncology. As the first marketed BTK inhibitor, Imbruvica performed steadily, with sales increasing by 13.7% in 2020 to reach US$5.314 billion. Venclexta (Venetoclax), the world's first marketed Bcl2 inhibitor, is gradually recognized as its importance in various anti-cancer combination therapies, with an increase of nearly 70% in 2020, reaching US$1.337 billion.
In 2020, AbbVie's oncology business revenue was US$6.651 billion, accounting for 14.5% of the company's total revenue, an increase of 20% year-on-year. As more and more BTK similar products and BTK C481S inhibitors are coming to market, it will threaten Imbruvica's market advantage. Looking at AbbVie's pipeline of oncology products under development, it seems that there is a lack of products with outstanding potential. AbbVie once again faces the need to get rid of dependence on a single product.
The two products with the highest revenue in Amgen's oncology field are Xgeva (Denosumab) and Kyprolis (Carfilzomib), with combined revenue of US$2.964 billion. Tumor biosimilar drugs Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab) contributed $1.365 billion in revenue for Amgen.
Amgen's oncology business is in urgent need of blockbuster innovative products. Undoubtedly, the KRAS G12C inhibitor Sotorasib is the most concerned, and has already submitted marketing applications in the United States, Europe, Canada, the United Kingdom, Brazil, and Australia.
In 2020, Amgen's oncology business revenue was US$8.037 billion, accounting for 31.6% of the company's total revenue, but the growth rate was only 2.1% year-on-year. This also indicates that if Amgen wants to maintain its position in the tumor market, it also urgently needs new blockbuster products as support.
Thanks to a portfolio of innovative products and biosimilars in breast cancer, non-small cell lung cancer, gastric cancer, ovarian cancer, renal cell carcinoma, and hematological malignancies, Pfizer's oncology business revenue in 2020 was US$10.867 billion, a year-on-year increase of 21%, accounting for 25.93% of the company's total revenue. Among them, the sales revenue of CDK4/6 inhibitor Ibrance was US$5.392 billion, and Xtandi (Enzalutamide) brought in cooperation revenue of US$1.024 billion, a year-on-year increase of 22%.
In 2020, AstraZeneca's oncology business revenue has maintained rapid growth, surpassing US$10 billion for the first time, reaching US$11.455 billion, accounting for 43% of its global revenue.
There are several strong products in AstraZeneca's tumor pipeline, including the third-generation EGFR inhibitor Tagrisso (Osimertinib), PD-L1 monoclonal antibody Imfinzi (Durvalumab), and the PARP inhibitor Lynparza (Olaparib), with a total contribution of 8.146 billion US dollars. The BTK inhibitor Calquence (Acalabrutinib) also achieved heavy volume in 2020, creating revenue of US$522 million.
In 2020, Johnson & Johnson's oncology business revenue was US$12.367 billion, accounting for 27.1% of its entire pharmaceutical business segment. Darzalex and Imbruvica maintained strong performance and are the two leading products of Johnson & Johnson's oncology business. Among them, Darzalex (Daratumumab) increased by nearly 40%, while Imbruvica (Ibrutinib) is still in a state of expansion. The two varieties have contributed more than US$8 billion in revenue to Johnson & Johnson, which is important for Johnson & Johnson's oncology field.
Johnson & Johnson also has generic drugs represented by Zytiga (Abiraterone acetate) and Velcade (Bortezomib), which brought in revenue of US$2.8 billion in 2020. Although these two former star drugs are facing generic competition and sales continue to decline, Johnson & Johnson's innovative products can better make up for it. Erleada (Apalutamide) brought in revenue of US$760 million in 2020 with a growth rate of 128.9%. The EGFR/MET bispecific antibody Amivantamab, which has attracted much attention, submitted a marketing application to the FDA for the treatment of advanced NSCLC with an insertion mutation of EGFR exon 20 with Phase I clinical data in December 2020. These two products are expected to become the new pillars of Johnson & Johnson's oncology business in the future.
In 2020, Novartis' oncology business revenue was 14.711 billion U.S. dollars, accounting for 30.2% of its pharmaceutical business revenue, a year-on-year increase of 2%, which is the lowest growth rate among the TOP10 companies, and it is likely to be surpassed by Johnson & Johnson next year.
The downturn in the oncology business is mainly due to the fact that Novartis has not established a new core product after imatinib lost its patent. Novartis has a large number of oncology drug products listed, but the overall performance is relatively balanced. The highest sales volume was Tasigna (Nilotinib), which was listed in 2007, with US$1.948 billion (+4%). Followed by the Tafinlar+Mekinist combination, bringing in revenue of $1.542 billion.
In 2020, Merck’s oncology business revenue was US$15.83 billion, accounting for 36.8% of its pharmaceutical business revenue. It can be said that Merck’s oncology business revenue is tied to Keytruda, of which US$14.38 billion comes from Keytruda’s commercial sales revenue, and the rest is also obtained by bundling Lynparza (Olaparib) and Lenvima (Lenvatinib) with Keytruda.
Keytruda's growth rate is as high as 30% in 2020, and the probability of breaking through 20 billion US dollars is high. This will not only continue to enlarge the scale of Merck's oncology business but also create conditions for Merck to continue to strengthen its dominant position in the oncology business.
Roche has always been the largest giant in the oncology drug market, but it will have to rank second in 2020. The merger of BMS and Celgene is an external factor, and the core reason is that its own products are facing upgrading. Avastin, Herceptin, and Rituxan were impacted by biosimilar drugs and the epidemic, resulting in a decline in the prescription rate. In 2020, the total revenue was only 12.947 billion Swiss francs, a decrease of 5.8 billion Swiss francs from 2019, a 30% year-on-year decrease. Roche's oncology business revenue in 2020 was 23.323 billion Swiss francs, accounting for 52.4% of its pharmaceutical business revenue, a year-on-year decline of 10%. It is the only one of the 10 companies whose sales have fallen.
However, Roche's product accumulation in the oncology field is still very deep. In the field of macromolecular tumor drugs, products such as Perjeta, Tecentriq and Kadcyla have achieved varying degrees of increase. In the field of small molecules, the ALK inhibitor Alecensa (Alectinib) also achieved a 40% increase, reaching 1.160 billion Swiss francs; Rozlytrek (Entrectinib) is also in the stage of market penetration, and the future is promising.
At the end of 2019, BMS completed the acquisition of Celgene. Although Opdivo (Nivolumab) saw its performance decline for the first time, it has Revlimid (Lenalidomide), Pomalyst (Pomalidomide), Sprycel (Dasatinib), Yervoy (Ipilimumab), Abraxane (Protein-bound paclitaxel) and Empliciti (Elotuzumab) and other oncology drug product portfolio, BMS has become the global oncology business leader. In 2020, oncology drug sales revenue reached US$28.419 billion, accounting for 66.84% of the company's overall revenue, an increase of 118.4% year-on-year.
Revlimid has become the new top brand of BMS, with annual sales reaching 12.106 billion US dollars. Together with Opdivo's 6.992 billion US dollars, the two contributed approximately 19.1 billion US dollars to BMS.
Huateng Pharma is a professional pharmaceutical intermediates supplier with a 34000m2 industrial park and a 5000m2 R&D base. It is dedicated to the production of pharmaceutical intermediates, there are some kinds of intermediates for oncology drugs such as Carfilzomib intermediates, Elagolix intermediates, Palbociclib intermediates, Enzalutamide intermediates, Alectinib intermediates and so on. There are also some anti-viral intermediates such as Oseltamivir intermediates, Baloxavir Marboxil intermediates and Remdesivir intermediates.
The Rise of Antibody-Drug Conjugates (ADCs) - 'Guided-Missile' Cancer Drugs
New Drug Approvals & Upcoming FDA Approvals 2021
Top 8 Blockbuster Peptide Drugs
What Are The World's Top Selling Drugs?